IP in Biopharma & Biotech
In this issue:
From the very first discoveries that lay the foundation for a life sciences busines to Phase III licencing, protection of Intellectual property is crucial to any product development associated with high risk and cost. And that’s especially true for the life sciences sector. In this upcoming EuroBiotech special on Intellectual Property, the field’s top experts from Europe and the US are invited to provide insight on the latest developments on topics such as IP and genetic resources, IP and clinical trail transparency, IP and biosimilar development, to name but a few.